Cardiovascular Diabetology最新文献

{"title":"Correction: Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population.","authors":"Maria Lembo, Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Stanislovas S Jankauskas, Paola Gallo, Roberto Piccinocchi, Carmine Morisco, Gaetano Piccinocchi, Luca Bardi, Stefano Cristiano, Giovanni Esposito, Giuseppe Giugliano, Fahimeh Varzideh, Maria Virginia Manzi, Bruno Trimarco, Gaetano Santulli","doi":"10.1186/s12933-025-02834-1","DOIUrl":"10.1186/s12933-025-02834-1","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"292"},"PeriodicalIF":8.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Expression of Concern: Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1.","authors":"Andrew Moore, Amol Shindikar, Ingrid Fomison-Nurse, Federica Riu, Pujika E Munasinghe, Thrishila Parshu Ram, Pankaj Saxena, Sean Coffey, Richard W Bunton, Ivor F Galvin, Michael J A Williams, Costanza Emanueli, Paolo Madeddu, Rajesh Katare","doi":"10.1186/s12933-025-02845-y","DOIUrl":"10.1186/s12933-025-02845-y","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"291"},"PeriodicalIF":8.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality.","authors":"Eugene Han, Kyung-Do Han, Yong-Ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park","doi":"10.1186/s12933-025-02824-3","DOIUrl":"10.1186/s12933-025-02824-3","url":null,"abstract":"<p><strong>Background: </strong>We investigated the risk of type 2 diabetes (T2DM) and related comorbidities including cardiovascular disease (CVD), and mortality, based on changes in metabolic dysfunction associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>We analyzed data from the Korean National Health Insurance Service for individuals aged ≥ 20 years. MASLD was defined as a fatty liver index (FLI), a prediction formula based on metabolic parameters, with a cutoff of ≥ 60. FLI measurements were compared within each individual over a 2 years period. Based on changes in FLI between two health checkups, individuals were classified into four categories; never MASLD (FLI consistently < 60), incident MASLD (FLI < 60 to ≥ 60), regressed MASLD (≥ 60 to < 60), and persistent MASLD (FLI consistently ≥ 60). The primary outcome was T2DM occurrence in the general population and myocardial infarction (MI), ischemic stroke, heart failure (HF) and mortality events in individuals with preexisting T2DM with adjustment for age, sex, smoking, alcohol drinking, and regular exercise.</p><p><strong>Results: </strong>In 4,397,808 individuals without T2DM, 229,475 (5.2%) developed T2DM during a median follow-up period of 7.3 years. The risk of incident T2DM was the highest in individuals with persistent MASLD compared to those who never had MASLD (HR = 5.28, 95% CI = 5.22-5.34). Individuals with incident or regressed MASLD also had increased risk of developing T2DM (HR = 3.30, 95% CI = 3.25-3.35 for incident MASLD, HR = 2.87, 95% CI = 2.82-2.92 for regressed MASLD). In a cohort of 636,520 individuals with preexisting T2DM followed for a median of 6.2 years, those with persistent MASLD had a higher risk of HF (HR = 1.28, 95% CI = 1.25 to 1.32), MI (HR = 1.15, 95% CI = 1.10 to 1.20), stroke (HR = 1.14, 95% CI = 1.09 to 1.19) and all-cause mortality (HR = 1.11, 95% CI = 1.09-1.14) compared to individuals who never had MASLD. Similarly, both incident and regressed MASLD were associated with an increased risk for HF, MI, stroke and all-cause mortality.</p><p><strong>Conclusions: </strong>Persistent MASLD is associated with an increased risk of incident T2DM, and further elevates the risk of CVD, and mortality among individuals with T2DM. Even individuals with incident or regressed MASLD exhibit an increased risk of these adverse outcomes compared to those who never had MASLD.</p><p><strong>Trial registration: </strong>N/A.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"289"},"PeriodicalIF":8.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of diabetes mellitus on myocardial function and clinical outcomes in patients with significant aortic regurgitation.","authors":"Yuting Tan, Yujie Zhang, Qiuyu Cai, Ruohan Zhao, Weidong Luo, Jingrong Jiang, Jiawei Shi, Tianshu Liu, Li Qiu, Jing Wang","doi":"10.1186/s12933-025-02843-0","DOIUrl":"10.1186/s12933-025-02843-0","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) causes myocardial dysfunction and has been linked to an increased risk of unfavorable cardiovascular events. However, the additive effects of T2DM on myocardial function and its association with clinical outcomes in patients with aortic regurgitation (AR) is undetermined. The study aimed to verify whether T2DM aggravates the deterioration of myocardial deformation and clinical outcomes in AR patients.</p><p><strong>Methods: </strong>A total of two hundred and fifty-five AR patients, differentiated by the presence or absence of T2DM [AR(T2DM+) and AR(T2DM-), respectively], along with 65 age-matched healthy individuals, underwent echocardiographic examination. Left ventricular (LV) and left atrial (LA) geometry and function, as well as LV global longitudinal strain (LVGLS) and left atrial reservoir strain (LARS), were compared among the different groups. Linear regression analyses were performed to identify the effects of T2DM on LVGLS and LARS in AR patients. In addition, major adverse cardiac events (MACEs) were recorded during follow-up. Kaplan-Meier analysis and Cox proportional hazards models were used to explore the relationship between T2DM and the risk of MACEs in AR patients.</p><p><strong>Results: </strong>Compared with controls, both AR(T2DM-) and AR(T2DM+) patients exhibited significantly increased LV and LA volumes, along with reduced LV and LA ejection fractions (all P < 0.05). LVGLS and LARS progressively declined from the controls to the AR (T2DM-) group to the AR (T2DM+) group (all P < 0.05). The presence of T2DM was independently associated with impaired LVGLS and LARS in patients with AR (both P < 0.05). During a median follow-up of 29 months, 42 MACEs were recorded. The incidence of MACEs was significantly higher in patients with T2DM than in those without (30.8% vs. 11.6%; χ² = 20.10; P < 0.001). In multivariable analysis adjusting for clinical and echocardiographic predictors and aortic valve surgery as a time-dependent covariate, T2DM remained independently associated with MACEs (HR, 2.22; 95% CI, 1.12-4.38; P = 0.022).</p><p><strong>Conclusions: </strong>In patients with AR, T2DM exerts an additive deleterious effect on both LA and LV function and is an independent predictor of MACEs. These findings underscore the need for earlier evaluation and intervention targeting cardiac function in the context of AR complicated by T2DM.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"290"},"PeriodicalIF":8.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct types of protein modifications in diabetic endothelial dysfunction.","authors":"Qianyou Zhou, Xintong Ge, Zhaojing Chen, Danyi Cao, Yun Chen, Jiahai Shi, Guoliang Meng","doi":"10.1186/s12933-025-02836-z","DOIUrl":"10.1186/s12933-025-02836-z","url":null,"abstract":"<p><p>Diabetes mellitus is a metabolic disorder characterized by persistent hyperglycemia. Chronic diabetes mellitus may contribute to endothelial dysfunction and result in various conditions such as diabetic retinopathy, diabetic nephropathy, neuropathy, peripheral vascular disease, and metabolic syndrome. Post-translational modifications (PTMs) refer to the chemical alterations made to amino acid residues on post-translational proteins, achieved through the addition or removal of specific functional groups. These modifications significantly influence a protein's structure and dynamics, ultimately regulating its localization, folding, interactions with other biomolecules, and overall activity, including mitochondrial function, insulin secretion, cellular development, and viability. The present review aims to provide a comprehensive overview of the different types of PTMs associated with diabetic endothelial dysfunction, including glycosylation, ubiquitination, phosphorylation, acetylation, lactylation, palmitoylation, SUMOylation, methylation, carbonylation, and other PTMs. Currently, several drugs and compounds have been found to improve endothelial cell function in diabetes mellitus by targeting PTMs. By elucidating the mechanisms through which these modifications contribute to endothelial dysfunction in diabetes, this review aspires to enhance the understanding of the condition and potentially facilitate the development of innovative therapeutic strategies aimed at addressing cardiovascular complications in individuals with diabetes.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"287"},"PeriodicalIF":8.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study.","authors":"Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park","doi":"10.1186/s12933-025-02846-x","DOIUrl":"10.1186/s12933-025-02846-x","url":null,"abstract":"<p><strong>Background: </strong>Renin-angiotensin-aldosterone system (RAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are key treatments for diabetic kidney disease. However, their independent and combined effects on end-stage kidney disease (ESKD) and mortality remain unclear. This study evaluates their impact, alone or in combination, on ESKD and all-cause mortality in patients with diabetes and hypertension.</p><p><strong>Methods: </strong>A nationwide cohort study using the Korean National Health Database included 261,783 individuals with type 2 diabetes and hypertension (2015-2017). Participants were grouped into (1) no RAS or SGLT2 inhibitors (reference), (2) SGLT2 inhibitors alone, (3) RAS inhibitors alone, and (4) combination therapy. Cox regression models were used to estimate hazard ratios (HRs) for ESKD, mortality, and their composite.</p><p><strong>Results: </strong>Over 5.38 years, 2,674 (1.02%) developed ESKD and 20,866 (7.97%) died. Combination therapy showed the greatest risk reduction for composite outcomes [HR 0.68, 95% confidence interval (CI) 0.56-0.82] and mortality (HR 0.68, 95% CI 0.56-0.83). SGLT2 inhibitors alone reduced composite risk (HR 0.71, 95% CI 0.61-0.84) and mortality (HR 0.68, 95% CI 0.57-0.81). RAS inhibitors alone had modest effects (HR 0.96, 95% CI 0.93-0.98) on composite outcomes and mortality (HR 0.94, 95% CI 0.91-0.97). Notably, only combination therapy was associated with lower ESKD risk (HR 0.63, 95% CI 0.37-1.07), but this was not statistically significant. SGLT2 inhibitors consistently reduced ESKD and mortality, while RAS inhibitors were beneficial mainly in non-SGLT2 inhibitor users.</p><p><strong>Conclusion: </strong>Combination therapy may provide the greatest renal and survival benefit for diabetic patients with hypertension. SGLT2 inhibitors alone significantly reduced mortality, while RAS inhibitors alone had a modest impact.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"288"},"PeriodicalIF":8.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.","authors":"Ansel Shao Pin Tang, Jovan Teng Yuan Hsu, Sheena Kar Shuan Chong, Jingxuan Quek, Genevieve Shek, Farisah Sulaimi, Kai En Chan, Vickram Vijay Anand, Bryan Chong, Anurag Mehta, Sue-Anne Toh, Mark Muthiah, Georgios K Dimitriadis, Carel W le Roux, Mark Yan-Yee Chan, Mamas Andreas Mamas, Yip Han Chin, Nicholas W S Chew","doi":"10.1186/s12933-025-02840-3","DOIUrl":"10.1186/s12933-025-02840-3","url":null,"abstract":"<p><strong>Background: </strong>Glucagon like peptide-1 receptor agonist (GLP-1RA) use in individuals with high atherosclerotic cardiovascular disease (ASCVD) risk reduces major adverse cardiovascular events (MACE). However, its clinical impact, in terms of numbers needed to treat (NNT), efficacy and safety profile in reducing the risk of myocardial infarction (MI) and the individual ASCVD constituents remain unclear.</p><p><strong>Methods: </strong>Electronic databases, Medline and Embase were reviewed for randomized trials from inception to 29 May 2025. Risk-reduction effect of GLP-1RA were pooled using pairwise meta-analysis with random-effects model. The primary outcome was MI, and secondary outcomes were the individual ASCVD constituents.</p><p><strong>Results: </strong>109,846 patients from 25 unique studies were included. Over a follow-up duration of 3.48 ± 1.51 (1.55 to 5.47) years, GLP-1RA reduced the risk of total MI (RR: 0.86, p < 0.01), with numbers needed to benefit (NNTB) of 207 to prevent one event of MI. Higher body mass index was associated with greater MI risk reduction (β: -0.09, p = 0.03) in GLP-1RA users. GLP-1RA reduced cardiovascular mortality (RR: 0.87, p < 0.01, NNTB 170), MACE (RR: 0.87, p < 0.01, NNTB 67) and stroke (RR: 0.88, p < 0.01, NNTB 335) compared to placebo. GLP-1RA commonly resulted in gastrointestinal side-effects amongst other systems (RR: 1.55, p  < 0.01, NNTH 9).</p><p><strong>Conclusion: </strong>GLP-1RA reduced the risk of MI, stroke, cardiovascular mortality and MACE in a broad range of patients with and without T2DM and/or prior ASCVD, supporting its role in ASCVD prevention, especially in the cohort with high BMI.</p><p><strong>Trial registration: </strong>Open Science Framework ( https://doi.org/10.17605/OSF.IO/7VXN5 ).</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"285"},"PeriodicalIF":8.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stress hyperglycemia ratio as a biomarker for early mortality risk stratification in cardiovascular disease: a propensity-matched analysis.","authors":"Mingxing Lei, Yan Li, Longcan Cheng, Nan Tang, Jie Song, Mi Song, QingQing Su, Mingxuan Liu, Shihui Fu, Feng Lin, Yuan Gao","doi":"10.1186/s12933-025-02812-7","DOIUrl":"10.1186/s12933-025-02812-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Stress hyperglycemia ratio (SHR) has emerged as a potential prognostic marker in critical illness, but its association with mortality in cardiovascular disease remains incompletely characterized. This study investigated the relationship between SHR and all-cause mortality in critically ill patients with cardiovascular disease, adjusting for a variety of confounding factors using propensity score matching (PSM).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A cohort of 3,352 critically ill patients with cardiovascular disease was stratified by SHR quartiles (Q1-Q4). Baseline characteristics, comorbidities (e.g., heart failure, diabetes), and severity scores (OASIS, APSIII, SOFA) were extracted from a large database containing de-identified health data patients admitted to the intensive care units (ICUs) of Beth Israel Deaconess Medical Center. PSM (670 matched pairs) balanced covariates between high (SHR &gt; 1.355) and low SHR groups. The associations between SHR and mortality risk (in-hospital, 28-day, 90-day, 365-day) were evaluated using Cox models, restricted cubic spline (RCS) analysis, and Kaplan-Meier survival curves. Cox proportional hazards models were implemented with three sequential adjustment levels: Model 1 (unadjusted); Model 2 (adjusted for demographic factors and comorbidities); and Model 3 (fully adjusted). Predictive performance of SHR combined with severity scores was assessed via area under the curve (AUC) improvement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Higher SHR quartiles exhibited greater comorbidity burden (e.g., acute kidney injury: 84.6% in Q4 vs. 79.7% in Q1, P &lt; 0.001) and severity scores (P &lt; 0.001). Unadjusted analysis showed a significant association between SHR and mortality, with Q4 having the highest in-hospital (Q4: 16.3% vs. Q1-Q3: 5.1-6.4%, P &lt; 0.001) and 365-day mortality (Q4: 29.2% vs. Q1-Q3: 15.7-16.9%, P &lt; 0.001). The RCS analysis revealed a U-shaped mortality risk, with average optimal SHR cutoffs of 1.355. After PSM, cox proportional hazard models confirmed that high SHR (Q4) remained associated with early mortality (in-hospital HR = 2.117, [95% CI: 1.223-3.665], P = 0.007; 28-day HR = 1.859, [95% CI: 1.100-3.141], P = 0.020) but not long-term outcomes (90-day mortality, P = 0.127; 365-day mortality, P = 0.123) in the Model 1. Similar trends were obtained after adjusting for demographic factors and comorbidities (Model 2) and in the fully adjusted model (Model 3). Adding SHR improved short-term mortality prediction performance (e.g., OASIS AUC: +0.034 for in-hospital, P &lt; 0.001), though benefits diminished post-PSM (e.g., OASIS: +0.012 for in-hospital, P = 0.009). However, incorporating SHR did not enhance the predictive performance of OASIS and SAPSII for 90-day and 365-day mortality prediction after PSM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Elevated SHR contributes to early mortality in patients with cardiovascular disease, even after rigorous confounder adjustment. The incremental predictiv","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"286"},"PeriodicalIF":8.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal coronary heart disease and mortality following hypertensive disorders of pregnancy and/or diabetes.","authors":"Angela M Malek, Dulaney A Wilson, Julio Mateus, Emily A Ash, Tanya N Turan, Daniel T Lackland, Kelly J Hunt","doi":"10.1186/s12933-025-02811-8","DOIUrl":"10.1186/s12933-025-02811-8","url":null,"abstract":"<p><strong>Background: </strong>Pre-pregnancy hypertension (HTN), hypertensive disorders of pregnancy (HDP), and diabetes have been linked to increased risk of post-pregnancy coronary heart disease (CHD) and all-cause mortality, but few studies have investigated their cumulative impact. This study aimed to assess the potential relationship between pre-pregnancy HTN, HDP, and diabetes and their cumulative impact on maternal cardiovascular outcomes defined as incident CHD and all-cause mortality within 5 years of delivery and over the entire study period (up to 14 years after delivery).</p><p><strong>Methods: </strong>This retrospective cohort study included 430,545 women aged 12-49 with ≥ 1 singleton, live birth in South Carolina (2004-2016) including non-Hispanic White (NHW; 59.2%), non-Hispanic Black (NHB; 31.4%), and Hispanic (9.4%) women. Birth certificate and hospitalization/emergency department (ED) visit data defined pre-pregnancy HTN, HDP (preeclampsia, eclampsia, gestational HTN), and diabetes (pre-pregnancy, gestational). Hospitalization/ED visit and death certificate data defined incident CHD and all-cause mortality. Covariate-adjusted Cox proportional hazard models were used to assess associations between CHD and mortality by exposure.</p><p><strong>Results: </strong>After adjustment for covariates relative to women without any of the three conditions (diabetes, pre-pregnancy HTN, HDP), incident CHD risk was increased within 5 years of delivery for women with diabetes (HR = 1.57; 95% CI 1.28-1.92), HDP (HR = 1.85; 95% CI 1.60-2.15), HDP and diabetes (HR = 2.29; 95% CI 1.73-3.03), HDP and pre-pregnancy HTN (HR = 3.13; 95% CI 2.66-3.68), and all three conditions (HR = 4.87; 95% CI 3.95-6.01). All-cause mortality risk was increased for diabetes (HR = 1.34; 95% CI 1.01-1.78), HDP and pre-pregnancy HTN (HR = 1.53; 95% CI 1.15-2.03), and all three conditions (HR = 2.25; 95% CI 1.51-3.36), but not HDP or HDP and diabetes.</p><p><strong>Conclusions: </strong>Within 5 years of delivery, incident CHD and all-cause mortality rates were highest for women with two or three conditions, specifically HDP, diabetes, and/or pre-pregnancy HTN, with all rates higher for NHB than NHW women. Thus, it is critical to implement clinical prevention strategies to improve risk factor screening and identification among women of child-bearing age.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"282"},"PeriodicalIF":8.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glyoxalase-1 overexpression attenuates arterial wall stiffening in diabetic mice.","authors":"Margarita G Pencheva, Eline Berends, Koen W F van der Laan, Alessandro Giudici, Petra Niessen, Jean L J M Scheijen, Philippe Vangrieken, Peter Leenders, Tammo Delhaas, Florian Caiment, Martina Kutmon, Fabiola M Trujillo, Kristiaan Wouters, Sébastien Foulquier, Bart Spronck, Koen D Reesink, Casper G Schalkwijk","doi":"10.1186/s12933-025-02823-4","DOIUrl":"10.1186/s12933-025-02823-4","url":null,"abstract":"<p><strong>Aims: </strong>Diabetes is a leading cause of mortality worldwide, primarily due to cardiovascular diseases (CVD). Arterial stiffness is a CVD predictor and is associated with increased mortality in diabetic individuals. In diabetes, the formation and accumulation of methylglyoxal (MGO), a highly reactive glycolysis by product and a major precursor in advanced glycation endproducts (AGEs) formation, has been implicated in CVD. In this study, we investigated the role of endogenous MGO in arterial stiffening in a mouse model of type 1 diabetes (T1D) overexpressing the MGO-detoxifying enzyme glyoxalase-1 (GLO1).</p><p><strong>Methods and results: </strong>Diabetes was induced in C57BL/6 J mice through 5-day streptozotocin injections. 17-week-old control, diabetic, and GLO1-overexpressing diabetic mice were used. Fasting glucose in diabetes and GLO1/diabetes was higher than control. Plasma, urine, and aortic MGO, AGEs, and cross-links were determined using ultra-performance liquid chromatography tandem mass spectrophotometry. MGO was increased in plasma and urine in diabetic mice, while GLO1 decreased MGO in urine. The AGE cross-link pentosidine in aorta was increased in diabetes and ameliorated by GLO1. Tail-cuff blood pressure and carotid-femoral pulse wave velocity were measured preceding euthanasia, and did not differ between groups. Descending thoracic aorta ex vivo passive biaxial arterial wall biomechanics were measured and diabetes showed elevated ex vivo PWV, which was attenuated by GLO1 overexpression. Material viscoelasticity was decreased in diabetes and normalised by GLO1 overexpression. Second harmonic generation imaging demonstrated a predominant axial orientation of diabetic collagen fibres, while GLO1/diabetes led to a uniform orientation. When comparing GLO1/diabetes and diabetes, bulk RNA sequencing revealed 137 differentially expressed genes affecting extracellular matrix organisation, cell-cell and cell-matrix communication and interaction pathways.</p><p><strong>Conclusion: </strong>In an animal model of T1D, GLO1 overexpression attenuates arterial stiffening at the underlying material levels, by modifying collagen ultrastructure and viscoelastic properties. Targeting MGO may provide a novel approach to prevent arterial T1D stiffening.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"283"},"PeriodicalIF":8.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}